|

Iparomlimab and Tuvonralimab (QL1706) Clinical Trials

2 actively recruiting trials

▲ +1 trial since June 2026

Pipeline

Phase 2: 2

Top Sponsors

  • Sun Yat-sen University1
  • Beijing Friendship Hospital1

Indications

  • Cancer2
  • Advanced Gastric Cancer1
  • Metastatic Gastric Cancer1
  • Uterine Cervical Neoplasms1
  • Locally Advanced1

Other2 trials

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Phase 2
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.